Comparison · NCT01843374-c30c8e6b
TREMELIMUMAB vs PLACEBO: Number of Participants Reporting Any Adverse Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TREMELIMUMAB vs PLACEBO: Number of Participants Reporting Any Adverse Event. Trial comparisons, record NCT01843374-c30c8e6b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01843374-c30c8e6b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.958 | 0.933 | 0.974 | wilson | |
| Risk in group 2 | 0.947 | 0.905 | 0.971 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0108 | -0.0239 | 0.0555 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.972 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 1.27 | 0.565 | 2.86 | log | |
| Number needed to treat, for one more participant with the outcome on TREMELIMUMAB than on PLACEBO | 92.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TREMELIMUMAB | Tremelimumab 10mg/kg | 364 | 380 | OG000 |
| Group 2 | PLACEBO | Placebo. | 179 | 189 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Reporting Any Adverse Event
- Description
- Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
- Time frame
- Day 1- 90 days post dose
- Population
- Safety population
Source ClinicalTrials.gov
Trial
- Title
- Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
- NCT number
- NCT01843374
- Phases
- PHASE2
- Conditions
- Unresectable Pleural or Peritoneal Malignant Mesothelioma
- Interventions
- Tremelimumab, Placebo
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2017-08-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01843374?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01843374-c30c8e6b